Down 3.3% today, more than its biotech peers' 1.4%; no story names it yet.
Fell on Nov 5
Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.
−3Long-term trend
CABA's Quality Score fell 3 points on Tue, Nov 10, to -10. Trading went back to normal after a busy day (3 chart checks stopped).
Follow CABA's trial news. Pro members can get an alert when Cabaletta Bio files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 82.7% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
TodayNo story names it yet.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
2 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -4.6% on average, higher 1 of 4 times.
About 7 quarters
Chief Medical Officer David J. Chang bought 8,800 shares on Jan 21. 7 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
CABA is #275 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 275 |
Expected to report Tue Mar 23, before the open (in 133 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
CABA's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Additionally, we are excited by progress in our juvenile dermatomyositis program and expect to have a robust dataset from these patients to include with our planned BLA submission in myositis in the first quarter of 2028, potentially enabling our eligibility for a Priority Review Voucher.”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -0.7% | -9.9% | not yet |
| Aug 13, 2026 | 0.0% | -4.9% | +8.8% |
| May 14, 2026 | -1.7% | +0.6% | -4.2% |
| Mar 23, 2026 | +6.1% | -4.1% | -8.8% |
RSI 41.2, MACD above signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CABA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
CABA scores -10 today, which Breakaway calls Poor. It is #275 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 10% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Cash lasts about 7 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CABA scores -10 today, which Breakaway calls Poor (below zero). That is #275 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CABA's -10.
Expected to report Tue Mar 23, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. CABA closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.